Literature DB >> 18231753

MDR1 and MDR3 genes and drug resistance to cisplatin of ovarian cancer cells.

Lirong Ren1, Lan Xiao, Jianli Hu.   

Abstract

To investigate the relationship between MDR1 and MDR3 gene and drug resistance to cisplatin of ovarian cancer cells. Two siRNAs (MDR1, MDR3) which specifically targeted MDR1 and MDR3 genes were transferred into A2780/DDP cells. Then double staining with Annexin-V-FITC/PI was used to detect cell apoptosis by the flow cytometry (FCM). A2780/DDP cell viability was determined by MTT. MDR1 and MDR3 mRNA were assessed by RT-PCR. Caspase-3 protein was detected by Western blotting. Transfection of MDR1 and MDR3 siRNA into A2780/DDP cells failed to reverse the drug-resistance of A2780/DDP cells to cisplatin (P>0.05). No significant difference in the apoptosis efficiency was observed between the MDR1 and MDR3 siRNA, pSuppressorNeo vector transfection cells and untreated cells (P>0.05). In the presence of cisplatin of different concentrations, the viability of A2780/DDP cells was not significantly decreased after the transfection. No changes in MDR1 and MDR3 mRNA were found in MDR1 and MDR3 siRNA-transfected A2780/DDP cells. As compared with pSuppressorNeo and untreated groups, no significant difference existed in the expression of MDR1 and MDR3 mRNA (P>0.05). The expression of caspase-3 protein in MDR1 and MDR3 siRNA transfected A2780/DDP cells was not significantly increased. It is concluded that multidrug resistance induced by cisplatin in ovarian carcinoma cell lines is not due to overexpression of MDR1 and MDR3 gene. The drug resistance of ovarian carcinoma cells to cisplatin is not mediated by P-glycoprotein.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18231753     DOI: 10.1007/s11596-007-0627-7

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  10 in total

1.  Quantitative and functional assay of MDR1/P170-mediated MDR in ascites cells of patients with ovarian cancer.

Authors:  Zoárd Tibor Krasznai; Elza Friedländer; András Nagy; Gábor Szabó; György Vereb; Katalin Goda; Zoltán Hernádi
Journal:  Anticancer Res       Date:  2005 Mar-Apr       Impact factor: 2.480

2.  MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping.

Authors:  A J Smith; A van Helvoort; G van Meer; K Szabo; E Welker; G Szakacs; A Varadi; B Sarkadi; P Borst
Journal:  J Biol Chem       Date:  2000-08-04       Impact factor: 5.157

3.  Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.

Authors:  Simona Mozzetti; Cristiano Ferlini; Paola Concolino; Flavia Filippetti; Giuseppina Raspaglio; Silvia Prislei; Daniela Gallo; Enrica Martinelli; Franco Oreste Ranelletti; Gabriella Ferrandina; Giovanni Scambia
Journal:  Clin Cancer Res       Date:  2005-01-01       Impact factor: 12.531

4.  Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells.

Authors:  Timothy C Cheng; Gerald Manorek; Goli Samimi; Xinjian Lin; Charles C Berry; Stephen B Howell
Journal:  Cancer Chemother Pharmacol       Date:  2006-01-11       Impact factor: 3.333

Review 5.  Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein.

Authors:  Hilary Thomas; Helen M Coley
Journal:  Cancer Control       Date:  2003 Mar-Apr       Impact factor: 3.302

6.  Bcl-2 overexpression enhances in vitro sensitivity against docetaxel in non-small cell lung cancer.

Authors:  Yoshimasa Inoue; Masatoshi Gika; Tomohiro Abiko; Takahiko Oyama; Yuriko Saitoh; Hitoshi Yamazaki; Masato Nakamura; Yoshiyuki Abe; Masafumi Kawamura; Koichi Kobayashi
Journal:  Oncol Rep       Date:  2005-02       Impact factor: 3.906

Review 7.  Promoting apoptosis as a strategy for cancer drug discovery.

Authors:  Stephen W Fesik
Journal:  Nat Rev Cancer       Date:  2005-11       Impact factor: 60.716

8.  Caspase-dependent cleavage of 170-kDa P-glycoprotein during apoptosis of human T-lymphoblastoid CEM cells.

Authors:  Irina Mantovani; Alessandra Cappellini; Pier Luigi Tazzari; Veronica Papa; Lucio Cocco; Alberto M Martelli
Journal:  J Cell Physiol       Date:  2006-06       Impact factor: 6.384

9.  Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines.

Authors:  A M Bergman; H M Pinedo; I Talianidis; G Veerman; W J P Loves; C L van der Wilt; G J Peters
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

10.  Phase I/II study of cisplatin combined with weekly paclitaxel in patients with advanced non-small-cell lung cancer.

Authors:  N Yoshimura; S Kudoh; T Mukohara; S Yamauchi; M Yamada; T Kawaguchi; Y Nakaoka; K Hirata; J Yoshikawa
Journal:  Br J Cancer       Date:  2004-03-22       Impact factor: 7.640

  10 in total
  4 in total

1.  MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.

Authors:  Andreas-Claudius Hoffmann; Peter Wild; Christina Leicht; Simone Bertz; Kathleen D Danenberg; Peter V Danenberg; Robert Stöhr; Michael Stöckle; Jan Lehmann; Martin Schuler; Arndt Hartmann
Journal:  Neoplasia       Date:  2010-08       Impact factor: 5.715

2.  ABCB4 is frequently epigenetically silenced in human cancers and inhibits tumor growth.

Authors:  Steffen Kiehl; Stefanie C Herkt; Antje M Richter; Liesa Fuhrmann; Nefertiti El-Nikhely; Werner Seeger; Rajkumar Savai; Reinhard H Dammann
Journal:  Sci Rep       Date:  2014-11-04       Impact factor: 4.379

3.  miR‑873 inhibits colorectal cancer cell proliferation by targeting TRAF5 and TAB1.

Authors:  Hui Gong; Lishan Fang; Yifan Li; Jihui Du; Bei Zhou; Xiu Wang; Hekai Zhou; Lingli Gao; Kaixin Wang; Juan Zhang
Journal:  Oncol Rep       Date:  2018-01-08       Impact factor: 3.906

4.  Overexpression of SMARCA2 or CAMK2D is associated with cisplatin resistance in human epithelial ovarian cancer.

Authors:  Xiaoli Xu; Zhiguo Zheng; Lanlan Jia; Shasha Suo; Bowen Liu; Tianning Shao; Qinqing Tu; Yuejin Hua; Hong Xu
Journal:  Oncol Lett       Date:  2018-07-10       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.